Flow Cytometry in Invasive Endometrial Carcinoma

  • Claes Tropé
  • Janne Kaern
  • Bengt Lindahl
  • Ignace Vergote
Part of the AGO Arbeitsgemeinschaft für Gynäkologische Onkologie book series (AGO)


The frequency of endometrial carcinoma is increasing world-wide, and in most countries in Western Europe and the United States, it is now the most common gynecologic malignancy. In Norway, endometrial carcinoma is the second most common cancer of the female genital tract. Approximately 500 new cases are anticipated in 1991, and about 120 will die of endometrial carcinoma every year in our country. More individualized therapy is probably essential in improving the prognosis for these high-risk patients [1].


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Sorbe B., Risberg B., Frankendahl B.: DNA ploidy, morphometry and nuclear grade as prognostic factors in endometrial carcinoma. Gynecol Oncol 38: 22, 1990PubMedCrossRefGoogle Scholar
  2. 2.
    Di Saia P.J., Creasman W.T., Boronow R.C., Lessing J.A.: Risk factors and recurrent patterns in stage I endometrial cancer. Amer J Obstet Gynecol 151: 1009, 1985Google Scholar
  3. 3.
    Iversen O.E.: Flow cytometric deoxyribunucleic acid index: A prognostic factor in endometrial carcinoma. Am J Obstet Gynecol 155: 770, 1986PubMedGoogle Scholar
  4. 4.
    Lindahl B., Aim O., Fernö M., Killander D., Längström E., Norgren A., Tropé C.: Prognostic value of flow cytometric DNA measurement in stage III endometrial carcinoma: Correlation with steroid receptor concentration, tumor myométrial invasion and degree of differentiation. Anticancer Research 7: 791, 1987PubMedGoogle Scholar
  5. 5.
    Iversen O.E., Utaker E, Skaarland E.: DNA ploidy and steroid receptors as predictors of disease course in patients with endometrial carcinoma. Acta Obstet Gynecol Scand 67: 531, 1988PubMedCrossRefGoogle Scholar
  6. 6.
    Geisinger K.R., Homesley H.D., Torgan T.M., Kute T.E., Marshall R.B.: Endometrial adenocarcinoma: A multiparameter clinico pathological analysis including the DNA profile and the sex steroid hormone receptors. Cancer 58: 1518, 1986PubMedCrossRefGoogle Scholar
  7. 7.
    Atkin N.: Prognostic significance of ploidy level in human tumors I carcinoma of the uterus. J Natl Cancer Inst 56: 909, 1976PubMedGoogle Scholar
  8. 8.
    Moberger B., Auer G., Forslund G., Mogerger G.: The prognostic significance in DNA measurements in endometrial carcinoma. Cytometry 5: 430, 1984PubMedCrossRefGoogle Scholar
  9. 9.
    Quillamor R.M., Furlong S.K., Hoschner J.A., Wynn R.M.: Relative prognostic significance of DNA flow cytometry and histologic grading in endometrial carcinoma. Gynecol Obstet Invest 26: 332, 1988PubMedCrossRefGoogle Scholar
  10. 10.
    Stendahl U., Wagenius G., Strang P., Tribukait B.: Flow cytometry in invasive endometrial carcinoma. Correlation between DNA content, S-phase rate and clinical parameters. In Vivo 2: 123, 1988PubMedGoogle Scholar
  11. 11.
    Britton L.C., Wilson T.O., Gaffey T.A., Lieber M.M., Wieland H.S., Podratz K.C.: Flow cytometric DNA analysis of stage I endometrial carcinoma. Gynecol Oncol 34: 317, 1989PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • Claes Tropé
  • Janne Kaern
  • Bengt Lindahl
  • Ignace Vergote

There are no affiliations available

Personalised recommendations